Journal Club #1-6: Claim CME Credits

Psychiatry Education Forum’s Journal Club is a new (and free) feature for Physician’s Guide for Clinical Psychiatry course subscribers. 

Today we posted our sixth journal club discussion today. Course subscribers will be able to claim a total of 1.50 AMA PRA Category 1 Credit(s) for these combined six journal club videos.

Each course subscriber will receive an email from us with details on how to claim these CME credits. Here is the list of six journal club videos posted so far:

(1) Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.

This journal club will answer the following ten clinically relevant questions:

  1. Is omega-3 fatty acids effective as augmentation or as monotherapy for MDD management?
  2. What dose of omega-3 fatty acid is considered therapeutic for treatment of MDD?
  3. What ratio of EPA/DHA is crucial for omega-3 fatty acids’s therapeutic benefit?
  4. Is pure EHA more efficacious than combination of EHA/DHA for MDD?
  5. What is the recommended minimum duration of treatment with omega-3 fatty acid for treatment of MDD?
  6. Is omega-3 fatty acid efficacious for recurrent depression?
  7. What are the common adverse events at therapeutic dose of omega-3 fatty acid?
  8. What additional lab work is required when using the higher dosages of omega-3 fatty acid?
  9. How to ensure the omega-3 fatty acid’s product quality before buying?
  10. Do omega-3 fatty acid’s response in MDD have relation with inflammatory biomarkers?

(2) Almost all Antipsychotics Result in Weight Gain: Meta-Analysis.

This journal club will answer the following six clinically relevant questions:

  1. Do ALL ANTIPSYCHOTICS result in mean increase in body weight with increased DURATION OF USE? 
  2. Which ANTIPSYCHOTIC and time period (DURATION) have more significant increase in weight gain?
  3. Which antipsychotics showed NO statistically significant weight change post baseline?
  4. Will switching to WEIGHT NEUTRAL ANTIPSYCHOTICS result in weight loss?
  5. How is weight gain in ANTIPSYCHOTIC NAIVE patients?
  6. Which factors are important to consider with weight gain from antipsychotics?

(3) Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study.

This journal club will discuss the progression of following schizophrenia symptoms domains:

  1. Positive Symptoms
  2. Negative Symptoms
  3. Depression/Anxiety
  4. Excitement/Hostility
  5. Neuro-Cognitive Impairment

(4) Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.

This journal club will be summarized in the following topics/questions:

  1. Lumateperone: Mechanism of action.
  2. Recommended dosage and titration.
  3. Lumateperone 28 mg vs 42 mg vs 84 mg: which one is preferred?
  4. When is the onset of response with Lumateperone?
  5. Lumateperone: Common adverse events.
  6. Association of Lumateperone with EPS, metabolic side effects, QTc prolongation and increase in suicidal ideations?
  7. How Lumateperone compares with other antipsychotics in terms of effect size for reduction in PANSS total symptoms?

(5) The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Bipolar Depression.

This journal club will compare the following two guidelines for bipolar depression management:

  • Canadian Network for Mood and Anxiety Treatments (CANMAT) and
  • International Society for Bipolar Disorders (ISBD) 2018 guidelines.

 

These guidelines will be compared in terms of First, Second and Third line treatment. This journal club will answer the following ten clinically relevant questions:

  1. Which medications are not recommended treatment for bipolar depression?
  2. Which Non-FDA approved medication is the first line treatment per both guidelines?
  3. Which FDA approved treatment is not recommended by Harvard South Shore program update?
  4. “Adjunctive” use of which medication is considered first line treatment per CANMAT & ISBD guidelines?
  5. Which one medication moved from second line treatment (in CANMAT & ISBD) to first line treatment (in Harvard South Shore program update)?
  6. “Monotherapy” with which medication is considered third-line treatment per CANMAT & ISBD guideline?
  7. Which medication(s) was recommended by CANMAT but NOT recommended by Harvard South Shore program update update due to safety concerns?
  8. Which antidepressant is preferred as an adjunctive treatment, over other antidepressants?
  9. Do aripiprazole have efficacy as monotherapy or as adjunct or no efficacy for bipolar depression?
  10. Which non-medication option was recommended by both guidelines?

(6) Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.

This journal club will discuss the basics of SEP-363856: Non–D2-Receptor-Binding Medication for Schizophrenia Treatment.

  1. Mechanism of Action for SEP-363856.
  2. Efficacy in Schizophrenia: PANSS Total, Positive, Negative and General Psychopathology scale.
  3. Side Effects Profile: Sleep, EPS, QTc Prolongation, Body Weight and Metabolic Parameters.

TOTAL 1.50 AMA PRA CATEGORY 1 CME CREDITS AVAILABLE FOR FIRST SIX JOURNAL CLUB LECTURES.

CME Credits™ Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute, LLC and Psychiatry Education Forum LLC. The PeerPoint Medical Education Institute, LLC is accredited by the ACCME to provide continuing medical education for physicians. The PeerPoint Medical Education Institute, LLC designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

JOIN PHYSICIAN’S GUIDE FOR CLINICAL PSYCHIATRY COURSE 

& GET ACCESS TO JOURNAL CLUB AND ADDITIONAL FEATURES:

JOIN PHYSICIAN’S GUIDE FOR CLINICAL PSYCHIATRY COURSE 

& GET ACCESS TO FOLLOWING FEATURES:

(1) ACCESS TO 250+ CLINICALLY RELEVANT CHAPTERS:

  • Each chapter is clinically relevant for your daily clinical practice.
  • Chapters and Sections are frequently updated.
  • Each chapter includes references: with either pdf article or pubmed link for each article.

(2) PSYCHIATRY EDUCATION FORUM’S JOURNAL CLUB:

  • Most recently published articles of direct clinical relevance of daily practice are discussed.
  • CME Credits available (as discussed above)

(3) PSYCHIATRY EDUCATION FORUM’S COFFEE CLUB:

  • Coffee Club will contain short discussions with clinical experts in the field of psychiatry. Join us, make good use of your much-deserved short breaks for high quality peer-to-peer learning.

Related Articles